A detailed history of Rafferty Asset Management, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 49,835 shares of ITOS stock, worth $361,802. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,835
Previous 35,985 38.49%
Holding current value
$361,802
Previous $534,000 4.87%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.09 - $17.97 $139,746 - $248,884
13,850 Added 38.49%
49,835 $508,000
Q2 2024

Aug 13, 2024

BUY
$10.33 - $18.09 $371,725 - $650,968
35,985 New
35,985 $534,000
Q3 2023

Nov 13, 2023

SELL
$10.95 - $14.6 $15,428 - $20,571
-1,409 Reduced 1.63%
85,189 $932,000
Q2 2023

Aug 11, 2023

SELL
$12.93 - $18.05 $354,954 - $495,508
-27,452 Reduced 24.07%
86,598 $1.15 Million
Q1 2023

May 11, 2023

BUY
$13.02 - $22.62 $148,219 - $257,506
11,384 Added 11.09%
114,050 $1.55 Million
Q4 2022

Feb 13, 2023

SELL
$17.77 - $21.6 $416,439 - $506,196
-23,435 Reduced 18.58%
102,666 $2.01 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $497,233 - $728,474
26,733 Added 26.9%
126,101 $2.4 Million
Q2 2022

Aug 12, 2022

BUY
$16.57 - $35.1 $34,250 - $72,551
2,067 Added 2.12%
99,368 $2.05 Million
Q1 2022

May 13, 2022

BUY
$31.92 - $47.45 $1.82 Million - $2.7 Million
56,985 Added 141.35%
97,301 $3.13 Million
Q4 2021

Feb 10, 2022

BUY
$26.23 - $47.86 $1.06 Million - $1.93 Million
40,316 New
40,316 $1.88 Million
Q2 2021

Aug 10, 2021

SELL
$17.9 - $36.1 $487,255 - $982,678
-27,221 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$30.86 - $44.2 $840,040 - $1.2 Million
27,221 New
27,221 $930,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.